Researchers at the University of California San Diego have uncovered how a single protein triggers two opposite responses in blood vessels—one inflammatory and one protective. This protein, a ...

A single receptor in blood vessels can trigger either harmful inflammation or protective healing, but scientists have ...

Researchers at the University of California San Diego have uncovered how a single protein triggers two opposite responses in blood vessels - one inflammatory and one protective. This protein, a ...

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can "educate" the immune system to find and destroy disease-causing cells throughout ...

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can "educate" the immune system to find and destroy disease-causing cells throughout ...

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...